A

Atlanta Diabetes Associates | Atlanta, GA

Research site
(Unclaimed)
Location
1800 Howell Mill Road, Suite 450, Atlanta, Georgia, United States of America
Site insights

Top conditions

Diabetes Mellitus (60 trials)

Type 1 Diabetes Mellitus (57 trials)

Type 2 Diabetes Mellitus (22 trials)

Hypoglycemia (5 trials)

Gastroparesis (4 trials)

Top treatments

LY900014
Relamorelin
Bococizumab
Glucose
Vildagliptin
Somapacitan
Sitagliptin
Semaglutide
LY3209590
LUM-201

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

17 of 105
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow (REAL 8)

The study compares two medicines for treatment of children born small and who stay small, or with Turner Syndrome, Noonan Syndrome, or idiopathic sho...

Enrolling
SGA, Turner Syndrome, Noonan Syndrome, ISS
Drug: Norditropin®
Drug: Somapacitan

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (m...

Enrolling
Type 2 Diabetes
Drug: Insulin glargine
Drug: IcoSema

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant i...

Enrolling
Prader-Willi Syndrome
Other: Placebo tablet
Drug: Pitolisant tablet

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52...

Enrolling
Central Precocious Puberty
Drug: Debio 4326
Locations recently updated

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Obicetrapib

This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric sub...

Active, not recruiting
Type 1 Diabetes
Device: MiniMed 780G System

This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effect...

Enrolling
Diabetes
Device: Blood glucose meter
Device: Eversense CGM System

The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes...

Enrolling
Type 2 Diabetes Treated With Insulin
Device: MiniMed™ 780G Insulin Pump system

INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using mul...

Active, not recruiting
Diabetes Mellitus, Type 1
Biological: Afrezza
Biological: Basal Insulin

The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with typ...

Enrolling
Type 1 Diabetes
Device: Subject's Current Diabetes Therapy
Device: 670G and 770G Insulin Pump

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the t...

Enrolling
Diabetic Kidney Disease
Drug: Placebo
Drug: INV-202

This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) an...

Active, not recruiting
Growth Hormone Deficiency
Drug: rhGH Norditropin® pen (34 µg/kg)
Drug: LUM-201

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in...

Enrolling
Diabetes Mellitus, Type 1
Drug: Lispro
Drug: HDV-Lispro

A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat ins...

Active, not recruiting
Diabetes Mellitus, Type 1
Diabetes Mellitus
Device: Eversense® CGM system

Trial sponsors

Medtronic logo

Medtronic (18 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems